In:
Science Immunology, American Association for the Advancement of Science (AAAS), Vol. 7, No. 75 ( 2022-09-02)
Abstract:
Despite the success of immune checkpoint blockade (ICB) in cancer, the efficacy is limited by immune-related adverse events (irAEs) that require treatment cessation. Thus, identifying peptides that induce both antitumor and irAE responses is crucial to improving ICB. Here, Berner et al. developed a method, DITAS (discovery of tumor-associated self-antigens) for detecting these peptides. DITAS involved analyzing the shared antigens between non–small cell lung cancer (NSCLC) and lung tissue, then performing immunopeptidomes, determining which HLA these peptides bound to, predicting the CD8 + T cell epitopes of these peptides, performing functional validation, and lastly identifying their candidate antigens. Using this method, the authors identified napsin A, which induced NSCLC and lung reactive T cells. Thus, DITAS could be used to identify irAE causing T cells.
Type of Medium:
Online Resource
ISSN:
2470-9468
DOI:
10.1126/sciimmunol.abn9644
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022
Bookmarklink